Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 3, 2008, Pages 673-682

  Lu, Ze ^b   Tsai, Max ^a   Lu, Dan ^a,b   Wang, Jie ^b   Wientjes, M Guillaume ^a   Au, Jessie L S ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b Optimum Therapeutics LLC   (United States)

^c 506 Riffe Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DRUG CARRIER; PACLITAXEL; POLYGLACTIN; TUMOR PENETRATING MICROPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG TARGETING; DRUG TRANSPORT; DRUG TUMOR LEVEL; FEMALE; GASTROINTESTINAL TOXICITY; INTESTINE CRYPT; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PARTICLE SIZE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RAPID DRUG RELEASE; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TUMOR MODEL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; KINETICS; MICE; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349141530     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.140095     Document Type: Article

References (40)

1. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, and DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955.
2. Alberts DS, Surwit EA, Peng YM, McCloskey T, Rivest R, Graham V, McDonald L, and Roe D (1988) Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 48:5874-5877.
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, and Burger RA (2006a) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43.
4. Armstrong DK, Fleming GF, Markman M, and Bailey HH (2006b) A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer(R)) in recurrent ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 103:391-396.
5. Chen CT, Au JL, and Wientjes MG (1998) Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res 4:277-282.
6. Demicheli R, Bonciarelli G, Jirillo A, Foroni R, Petrosino L, Targa L, and Garusi G (1985) Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration. Tumori 71:63-68.
7. Elias DM and Sideris L (2003) Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 12:755-769, xiv. Review.
8. Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, and Conte PF (2000) Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 76:157-162.
9. Gan Y, Wientjes MG, Schuller DE, and Au JLS (1996) Pharmacodynamics of taxol in human head and neck tumors. Cancer Res 56:2086-2093.
10. Goldberg KE (2006) Phase III trial shows benefit for old drug, device, for ovarian cancer; will practice change? The Cancer Letter 32:1-4.
11. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, and Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59:3776-3782.
12. Hagiwara A, Takahashi T, Iwamoto A, Yoneyama C, Itoh M, and Sasabe T (1990) Affinity of intraperitoneally injected activated carbon particles adsorbing mitomycin C to tumor surface of Yoshida sarcoma. Anticancer Drug Des 5:359-369.
13. Howell SB, Pfeifle CE, and Olshen RA (1984) Intraperitoneal chemotherapy with melphalan. Ann Intern Med 101:14-18.
14. Jackson JK, Skinner KC, Burgess L, Sun T, Hunter WL, and Burt HM (2002) Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res 19:411-417.
15. Jang SH, Wientjes MG, and Au JL (2001a) Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs 19:113-123.
16. Jang SH, Wientjes MG, and Au JL (2001b) Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 296:1035-1042.
17. Kerr DJ and Los G (1993) Pharmacokinetic principles of locoregional chemotherapy. Cancer Surv 17:105-122.
18. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, and Langer R (2006) Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res A 77:351-361.
19. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, and Au JL (1999) Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 290:871-880.
20. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, and McVie JG (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25:389-394.
21. Los G, Verdegaal EM, Mutsaers PH, and McVie JG (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28:159-165.
22. Lu D, Wientjes MG, Lu Z, and Au JL (2007) Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther 322:80-88.
23. Markman M, Brady MF, Spirtos NM, Hanjani P, and Rubin SC (1998) Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 16:2620-2624.
24. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, and Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007.
25. Markman M, Reichman B, Hakes T, Rubin S, Lewis JL Jr, Jones W, Barakat R, Curtin J, Almadrones L, and Hoskins W (1993) Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol 50:100-104.
26. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, and Phillips M (1992) Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol 10:1485-1491.
27. Markman M and Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988-994.
28. Monk BJ, Surwit EA, Alberts DS, and Graham V (1988) Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. Semin Oncol 15:27-31.
29. Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, et al. (2003) Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9:5896-5901.
30. O'Dwyer PJ, LaCreta FP, Daugherty JP, Hogan M, Rosenblum NG, O'Dwyer JL, and Comis RL (1991) Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res 51:2041-2046.
31. Ozols RF, Bookman MA, and Young RC (2006) Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med 354:1641-1643.
32. Shive MS and Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5-24.
33. Song D and Au JL (1995) Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Appl 663:337-344.
34. Tauchi PS, Caraway N, Truong LD, Kaplan AL, and Ramzy I (1996) Serous surface carcinoma of the peritoneum: useful role of cytology in differential diagnosis and follow-up. Acta Cytol 40:429-436.
35. Topuz E, Saip P, Aydmer A, Salihoǧlu Y, Berkman S, and Bengisu E (1998) Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. Eur J Gynaecol Oncol 19:265-270.
36. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, and Au JL (2007) Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm Res 24:1691-1701.
37. Visscher GE, Robison RL, Maulding HV, Fong JW, Pearson JE, and Argentieri GJ (1985) Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co- glycolide) microcapsules. J Biomed Mater Res 19:349-365.
38. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, and Cella D (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:437-443.
39. Zheng JH, Chen CT, Au JL, and Wientjes MG (2001) Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS Pharm Sci 3:E15.
40. Zimm S, Cleary SM, Lucas WE, Weiss RJ, Markman M, Andrews PA, Schiefer MA, Kim S, Horton C, and Howell SB (1987) Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res 47:1712-1716.